Lenabasum
- Generic Name
- Lenabasum
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36O4
- CAS Number
- 137945-48-3
- Unique Ingredient Identifier
- OGN7X90BT8
- Background
Ajulemic acid has been used in trials studying the treatment of Cystic Fibrosis, Dermatomyositis, and Diffuse Cutaneous Systemic Sclerosis.
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
- Conditions
- Dermatomyositis
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT03813160
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Pittsburgh, Division of Rheumatology, Pittsburgh, Pennsylvania, United States
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT03451045
- Locations
- 🇦🇹
Cystic Fibrosis Centre Innsbruck Medical University of Innsbruck, Dept. for Child and Adolescent Health, University Clinic for Paediatrics, Cardiology, Pneumology, Allergology, Cystic Fibrosis, Innsbruck, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
🇧🇪Universitair Ziekenhuis Brussel, Brussels, Belgium
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT03398837
- Locations
- 🇺🇸
John Hopkins University, Scleroderma Center, Baltimore, Maryland, United States
🇺🇸The Steffens Scleroderma at The Center for Rheumatology, Albany, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
JBT-101 in Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus ErythematosusLupusSLE
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2022-11-18
- Target Recruit Count
- 109
- Registration Number
- NCT03093402
- Locations
- 🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Duke University, Durham, North Carolina, United States
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02466243
- Locations
- 🇺🇸
University of Pennsylvania Perlman School of Medicine, Philadelphia, Pennsylvania, United States
Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT02465450
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇬🇧Belfast City Hospital, Belfast, United Kingdom
🇵🇱Instytut Gruźlicy i Chorób Płuc I Klinika Chorób Płuc, Warszawa, Poland
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02465437
- Locations
- 🇺🇸
Arthritis Association of Southern CA, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸John Hopkins Scleroderma Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.